Evidence map›Paper›PMID 38702807›Full record

ArticleVirology journal2024

Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda.

Zacchaeus Anywaine, Christian Hansen, George M Warimwe, Ggayi Abu-Baker Mustapher, Luke Nyakarahuka, Stephen Balinandi, Alex Riolexus Ario, Julius J Lutwama, Alison Elliott, Pontiano Kaleebu

Abstract read
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Has the epidemiologic conundrum of Rift Valley fever changed?Tropical animal health and production · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zacchaeus AnywaineDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK. Zacchaeus.Anywaine@mrcuganda.org.
Christian HansenMRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
George M WarimweCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Ggayi Abu-Baker MustapherDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Luke NyakarahukaDepartment of Arbovirology, Emerging and Re-emerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.
Stephen BalinandiDepartment of Arbovirology, Emerging and Re-emerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.
Alex Riolexus ArioNational Institute of Public Health, Ministry of Health, Kampala, Uganda.
Julius J LutwamaDepartment of Arbovirology, Emerging and Re-emerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.
Alison ElliottDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Pontiano KaleebuMedical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Plot 51 - 59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.

Funding

Joint funding by the UK Medical Research Council (MRC) part of UK Research and Innovation (UKRI) and the UK Foreign, Commonwealth and Development Office (FCDO) under the MRC/FCDO Concordant agreement; and EDCTP2 programme supported by the European Union MC_UU_00027The Oak Foundation fellowship and The Wellcome Trust 203077_Z_16_ZUK Biotechnology and Biological Sciences Research Council (BBSRC) and the Medical Research Council (MRC)/Department of Health, through the UK Vaccines Network 16/107/02Wellcome Trust
6 · The paper itself

Abstract

backgroundRift Valley fever (RVF) is a zoonotic viral disease of increasing intensity among humans in Africa and the Arabian Peninsula. In Uganda, cases reported prior to 2016 were mild or not fully documented. We report in this paper on the severe morbidity and hospital-based mortality of human cases in Uganda.

methodsBetween November 2017 and March 2020 human cases reported to the Uganda Virus Research Institute (UVRI) were confirmed by polymerase chain reaction (PCR). Ethical and regulatory approvals were obtained to enrol survivors into a one-year follow-up study. Data were collected on socio-demographics, medical history, laboratory tests, potential risk factors, and analysed using Stata software.

resultsOverall, 40 cases were confirmed with acute RVF during this period. Cases were not geographically clustered and nearly all were male (39/40; 98%), median age 32 (range 11-63). The median definitive diagnosis time was 7 days and a delay of three days between presumptive and definitive diagnosis. Most patients (31/40; 78%) presented with fever and bleeding at case detection. Twenty-eight (70%) cases were hospitalised, out of whom 18 (64%) died. Mortality was highest among admissions in regional referral (11/16; 69%) and district (4/5; 80%) hospitals, hospitalized patients with bleeding at case detection (17/27; 63%), and patients older than 44 years (9/9; 100%). Survivors mostly manifested a mild gastro-intestinal syndrome with nausea (83%), anorexia (75%), vomiting (75%), abdominal pain (50%), and diarrhoea (42%), and prolonged symptoms of severe disease including jaundice (67%), visual difficulties (67%), epistaxis (50%), haemoptysis (42%), and dysentery (25%). Symptom duration varied between two to 120 days.

conclusionRVF is associated with high hospital-based mortality, severe and prolonged morbidity among humans that present to the health care system and are confirmed by PCR. One-health composite interventions should be developed to improve environmental and livestock surveillance, prevent infections, promptly detect outbreaks, and improve patient outcomes.

Indexed as

Rift Valley FeverAdolescentAdultChildFemaleHospital MortalityHumansMaleMiddle AgedMorbidityRift Valley fever virusRisk FactorsUgandaYoung Adult

Identifiers

PMID38702807
PMCPMC11069174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.